Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

BTOS-HA

Small molecule · Agonist of alpha-2A adrenergic receptor (ADRA2A) · developed by Bausch & Lomb

Phase 3 Most advanced trial (none active)

BHC Developer

1 Registered trials

What is BTOS-HA?

BTOS-HA is a brimonidine tartrate ophthalmic solution with sodium hyaluronate administered as topical ocular drops. Brimonidine is an alpha-2A adrenergic receptor agonist. The drug is studied for ocular redness.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Small molecule
Targets: alpha-2A adrenergic receptor (ADRA2A)
Mechanism: Agonist of alpha-2A adrenergic receptor (ADRA2A)
Therapy area: Ophthalmology
Developer: Bausch & Lomb Incorporated (BHC)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 3

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT06803654	Phase 3	Ocular Redness	Completed	BHC

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Ocular Redness

Other drugs acting on ADRA2A

Brimonidine FDA approved BXCL501 FDA approved Clonidine FDA approved Dexmedetomidine FDA approved

More from Bausch & Lomb

Adapalene / Benzoyl Peroxide / Clindamycin FDA approved Brodalumab FDA approved Bupropion FDA approved Halobetasol Propionate And Tazarotene FDA approved IDP-118 FDA approved IDP-126 FDA approved Lifitegrast FDA approved Perfluorohexyloctane FDA approved Plecanatide FDA approved Rifaximin FDA approved Timolol FDA approved BL1107 Phase 2

Sources

ClinicalTrials.gov NCT06803654

Updated Oct 3, 2026. Something wrong or missing? Report it on the BHC page.

Follow BHC, the company behind BTOS-HA

See BHC's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

BHC catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z